News

PipelineReview.com4h
Sobi and Apellis: Aspaveli®/Empaveli® Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney Diseases
STOCKHOLM, Sweden I June 6, 2025 I Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase 3 ...
PipelineReview.com4h
Spur Therapeutics Presents Positive New Preclinical Data on Its Gene Therapy Candidate for GBA1 Parkinson’s Disease at 2025 GBA1 Meeting
Data show SPR301 lowered α-synuclein, a hallmark of Parkinson’s disease, in cellular models, indicating potential for efficacy at doses with favorable safety ...
PipelineReview.com4h
Novo Nordisk to present phase 3 trials across hemophilia portfolio, reinforcing commitment to research in rare blood disorders, at ISTH 2025
PLAINSBORO, NJ, USA I June 6, 2025 I Novo Nordisk today announced that new hemophilia data will be presented at the upcoming International Society on ...
PipelineReview.com4h
OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies
TAIPEI, Taiwan I June 06, 2025 I OBI Pharma, Inc. (OBI), a clinical-stage global oncology company specialized in the development of novel cancer therapies ...
PipelineReview.com4h
Kelun-Biotech Announces Approximately US$250 Million Placement
CHENGDU, China I June 5, 2025 I On June 5, 2025, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced ...
PipelineReview.com7h
Linerixibat New Drug Application (NDA) accepted for review by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC)
LONDON, UK I June 02, 2025 I GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has accepted for review the NDA for ...